Ginseng plant extract plays a leading role in the export of traditional Chinese Medicine

In the first quarter of May 30, ginseng reached the highest price in the history of export Planting and lifting also became the first commodity category of more than 1 billion US dollars in the export of traditional Chinese medicine Both of them performed well, but overall, there was still a lot of pressure on the export of traditional Chinese medicine in the year In the first quarter, China's import and export of traditional Chinese medicine reached 758 million US dollars, a year-on-year increase of 9.42%, of which the import was 169 million US dollars, a year-on-year increase of 20.46%; while the export of traditional Chinese medicine was 589 million US dollars, a year-on-year increase of 6.62% However, in terms of export volume, the decline of traditional Chinese medicine and health care products was large, which led to a rare sharp decline in the export volume of traditional Chinese medicine in the first quarter, down 18% year on year There is no lack of bright spots compared with the export, the import of traditional Chinese medicine increased significantly year on year, mainly due to the significant increase in the import of licorice and its extract Licorice is one of the most important protected resource products in China and one of the national export quota management commodities It is widely used in medicine, food, cosmetics, cigarettes and other industries, and the global demand is increasing In order to alleviate the shortage of domestic resources, China has taken some encouraging measures for licorice import enterprises since 2008 After that, the import volume of licorice in China has increased year by year, reaching a record high in 2011 In the first quarter of this year, the demand for licorice at home and abroad is still very strong, and the import growth of licorice in China has far exceeded the export growth Uzbekistan, Kazakhstan and other countries are rich in wild licorice resources with good quality, accounting for more than 80% of the total import of licorice in China In terms of export, the traditional international market of traditional Chinese medicine still maintains its advantages, while emerging markets such as Russia show vitality Japan, South Korea, ASEAN, Hong Kong, China and the United States are still the main export markets of traditional Chinese medicine Due to the single variety and serious homogenization competition, the export pressure of pharmaceutical enterprises has increased significantly The products of many time-honored Chinese patent medicine enterprises are unique and special, with fixed market share and stable customers, and can control the initiative of foreign quotation Most of these enterprises quote in RMB, thus effectively avoiding the risk of exchange rate fluctuation to a large extent Russian health products market is one of the most attractive emerging markets in the world There are certain differences and complementarities between Russia and China in the development of pharmaceutical industry With the maturity and openness of Russia's market, the export of various kinds of traditional Chinese medicine products to Russia exploded for the first time last year At this Canton Fair, China's massage appliances and some health care products are favored by Russian businessmen In 2011, the export price of ginseng in China was US $36770 / ton, an increase of 84% over the same period of last year In the first quarter of this year, the export price reached US $43000 / ton, a record high The main export areas of ginseng in China are Japan, Italy, Germany, the Netherlands, Hong Kong, China and Taiwan Since 2011, the market demand of Italy, Germany and the Netherlands has been increasing and the export price has been rising However, the current price of ginseng in China is still far lower than that in South Korea (the export price of Korean ginseng is as high as 179603 US dollars / ton) Korean ginseng enterprises have been vigorously exploring the international market for many years The main export areas are basically the same as Chinese ginseng, but their brand added value is high In the main export markets, Korean ginseng occupies the high-end market, while Chinese ginseng only occupies the low-end market In the first quarter of this year, the export price of ginseng in China began to rise sharply, on the one hand, because of product upgrading, such as processing ginseng crude products into extracts, or starting to operate organic products After the added value of products increases, not only the market demand is more vigorous, but also the price can be accepted by customers On the other hand, the awareness of ginseng brand in China is constantly improving There were more than 30 ginseng brands registered in Jilin Province, the main place of ginseng production before However, the product output of each brand is not large, the market coverage is narrow, and there is no national brand Correspondingly, Korean ginseng's most famous brand, zhengguanzhuang, has an annual output value of more than 2 billion US dollars It has an absolute advantage in Korean ginseng brand China lacks the big brand of ginseng products, and also lacks the international competitiveness of ginseng industry However, on January 15 this year, the first "Changbaishan ginseng" brand product store was put into trial operation and achieved a good start This year, Jilin has established the brand marketing mode of "Changbaishan ginseng", using various publicity modes to form brand cohesion and brand benefit as soon as possible At the same time, China's policy of promoting internal and external participation and raising prices from the source has also achieved initial results In the past, China stipulated that ginseng could only be used for medicine but not for food, which restricted the development of ginseng health food in China In developed countries such as South Korea and the United States, ginseng can be used in food, so ginseng food is very popular in these countries Since March 1, Jilin Province has implemented the new method of ginseng management, ginseng can be directly added to various foods as raw materials of food and beverage During the Canton Fair, China Chamber of Commerce for the import and export of medical and health products visited some Fusong ginseng enterprises Fusong ecological ginseng industry company reported that it had obtained the batch number of food, so it can start to use ginseng as a pilot for domestic food sales With the implementation of the new measures for ginseng management in Jilin Province, China's ginseng health food will open up a broad new road Plant extract industry in spring is the fastest growing industry in the export industry of traditional Chinese medicine, which can also be said to be the "sunrise industry" forever In the first quarter, the export continued to maintain a stable growth At the end of last year, the national development and Reform Commission and the Ministry of industry and information technology jointly issued the 12th Five year development plan for the food industry, which clearly stated that "we will encourage and support the development of the natural pigment and plant extract industry, and continue to develop advantageous export products" In 2011, the export of plant extracts reached US $1.13 billion, a year-on-year increase of 47%, becoming the first commodity category with more than US $1 billion of export of traditional Chinese medicine In the first quarter, China's export of extract reached US $299 million, up 11.71% year on year, accounting for 50.69% of the total export of traditional Chinese medicine The largest export category of plant extracts is natural pigment products, such as paprika red pigment, lutein and other food pigments In addition, flavors and fragrances extract is also an obvious growth in export volume Although the global economic growth slows down, the demand for plant extracts, as a rigid demand product, is still strong in the major economies of the world The import of plant extracts in the three major markets of the United States, Japan and the European Union increased significantly, especially in the United States and Japan In the first quarter, China's export of extracts to the two countries increased by 31.69% and 27.74% respectively In recent years, the export pressure of traditional Chinese medicine products has been greatly influenced by domestic and foreign regulations, including the requirements of the United States for the implementation of cGMP quality certification of traditional Chinese medicine preparations and the formal implementation of the EU registration directive on traditional botanical drugs The improvement of access standards has formed a new challenge for the export of Chinese patent medicines to the above countries In addition, the detection standards of pesticide residue and heavy metal content of traditional Chinese medicine are different at home and abroad, and the detection standards of commodity inspection departments in various provinces are not completely standardized and unified, which also affects the export of traditional Chinese medicine to a certain extent According to the exhibitors of traditional Chinese medicine at the Canton Fair, there were a large number of pharmaceutical merchants from Taiwan during the fair, but they were cautious in purchasing This is mainly due to the impact of local control measures on imported Chinese herbal medicines Since September 1, 2011, Taiwan, China has fully implemented the source management and border management system for imported Chinese herbal medicines, and required the mainland Chinese herbal medicines to provide official documents for testing according to Taiwan's testing methods when they are transported to Taiwan Moreover, the pesticide residues and heavy metal limits of some Chinese herbal medicines are higher than those of Japan and Japan The Republic of korea In the first quarter, the export volume of 10 products controlled by Taiwan authorities, including jujube, eucommia, Poria, chuanxiong, Atractylodes macrocephala, white peony, rehmannia, angelica, Astragalus and liquorice, declined to a certain extent After the EU botanical drug registration directive came into force last year, the export scale of Chinese patent medicines to the EU has also shrunk to some extent However, during this period, the national government departments and China Chamber of Commerce for the import and export of medical and health products and other units held many training meetings to provide consulting and training services for enterprises' overseas registration It is proposed that the Netherlands attaches great importance to promoting the entry of traditional Chinese medicine into the market of the country and the European Union, and that the local people are more welcome to traditional Chinese medicine It is suggested that domestic enterprises can first open from these more recognized countries of traditional Chinese medicine Breakthrough point This year, Chengdu Di'ao Xinxuekang was finally listed as a drug in the Netherlands, which has taken a solid step towards the internationalization of Chinese traditional medicine Recently, the problem capsule incident has also triggered a certain trust crisis Recently, Hong Kong has begun to require the Chinese patent medicine export enterprises to provide the manufacturer information and relevant inspection reports of the product capsules, while Singapore also said that it may carry out spot check on the products with capsule packaging in China at any time In general, due to the severe world economic environment, the increase of enterprise cost and exchange rate, the export volume of traditional Chinese medicine in the first quarter has declined significantly, and the import and export of traditional Chinese medicine will face great challenges in 2012 In this case, the relevant departments should maintain the existing export preferential policies to create a good environment for the export of enterprises For example, the normal export order of enterprises should not be affected when the "capsule" is under scientific and standardized supervision Many enterprises suggest that the supervision should be carried out by sections and levels, and the drug regulatory department should strengthen the source review of capsule manufacturing enterprises.